NCT01644877已完成2 期
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 111
- 试验地点
- 45
- 主要终点
- Clinical Stability
研究概览
简要总结
This protocol will seek to enroll immunocompromised patients who are on supplemental oxygen and diagnosed with a parainfluenza infection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥12 years
- •Able to provide informed consent, child assent with parental consent or surrogate consent when applicable
- •Currently on invasive mechanical ventilation or noninvasive positive pressure ventilation (CPAP or bilevel positive airway pressure) or requiring > 2LPM supplemental oxygen therapy to maintain O2 saturation > 90% due to hypoxemia
- •Immunocompromised, as defined by one of the following: Autologous or Allogeneic hematopoietic cell transplantation (HSCT); Lung or lung-heart transplantation; Subjects treated with chemotherapy for hematologic malignancies; Subjects treated with chemotherapy for solid tumor malignancies
- •Confirmed parainfluenza at screening by one of the following methods using any sample type: Respiratory Virus Panel, Direct fluorescent antibody (DFA), Qualitative/quantitative RT-PCR test for parainfluenza virus performed at the local laboratory (a confirmatory PCR test will be done at the central lab but is not required to start the patient on study).
- •Confirmed PIV lower tract disease for subjects on mechanical ventilation will be defined as PIV detection in bronchoalveolar lavage (BAL) or biopsy within last 7 days of screening
- •Confirmed PIV lower tract disease for subjects on non-invasive positive pressure ventilation or supplemental oxygen will be defined as all of the following within the last 7 days of screening: New pulmonary infiltrate on chest imaging and at least one PIV sign and/or symptom as defined in section 10.3.6
- •Female subjects of child-bearing potential who are capable of conception must be post-menopausal (one year or greater without menses), surgically incapable of childbearing, or practicing two effective methods of birth control. Acceptable methods include abstinence, intrauterine device, spermicide, barrier, male partner surgical sterilization and hormonal contraception. A female subject ≥18 years of age and of child bearing potential must agree to practice two acceptable methods of birth control during the study period. All reproductive female subjects must have a negative serum pregnancy test during the screening visit.
- •Male subjects must agree to use medically accepted form of contraception during the study period. Abstinence is an acceptable method of contraception.
排除标准
- •Psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion of the principal investigator, would affect patient safety and/or compliance.
- •Any significant finding in the patient's medical history or physical examination that, in the opinion of the investigator, would affect patient safety or compliance with the dosing schedule.
- •In the opinion of the Investigator, subjects with a low chance of survival during the first 5 days of treatment.
- •Subjects treated with oral, aerosolized or intravenous (IV) ribavirin for the treatment of PIV. A forty-eight hour (48 hr) wash out period prior to randomization is allowed.
- •Subjects with a history of RSV or MPV
- •Subjects taking any other investigational drug used to research or treat PIV.
- •Subjects with a history of allergic reactions to lactose.
- •Subjects with a history of documented Pseudomonas aeruginosa pneumonia confirmed radiographically and by culture from BAL.
研究组 & 干预措施
DAS181
Experimental
DAS181-F02, 4.5 mg qd x 10 days
干预措施: DAS181 dry powder, formulation F02 (Drug)
Lactose Placebo
Placebo Comparator
placebo, 4.5 mg qd x 10 days
干预措施: Lactose Placebo (Drug)
结局指标
主要结局
Clinical Stability
时间窗: 45 days
Clinical stability survival (CSS) rate is defined as subjects who meet the clinical stability criteria and are alive at Study Day 45 (Responders) compared to those who have not met clinical stability criteria or have expired regardless of stability status (Non-responders)
次要结局
- Clinical Stability(45 days)
- Mortality(45 days)
研究者
研究点 (45)
Loading locations...
相似试验
已完成
2 期
Studying Complement Inhibition in Early, Newly Developing Septic Organ DysfunctionSevere SepsisSeptic ShockNCT02246595InflaRx GmbH72
已完成
2 期
Study of Plozasiran (ARO-APOC3) in Adults With Mixed DyslipidemiaMixed DyslipidemiaNCT04998201Arrowhead Pharmaceuticals353
进行中（未招募）
2 期
Alpha/Beta T and CD19+ Depleted Peripheral Stem Cells for Patients With Primary ImmunodeficienciesImmunodeficienciesImmune Dysregulation SyndromesNCT02990819Children's Hospital of Philadelphia60
已完成
2 期
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV InfectionSmallpoxNCT02038881Bavarian Nordic87
终止
2 期
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With MelanomaStage III MelanomaStage IV MelanomaNCT01026051Mannkind Corporation5